Acasti Pharma Inc(ACST)stock report

Acasti Pharma Inc is a Canada-based biopharmaceutical company. The Company is focused on the research, development and commercialization of prescription drugs using omega 3 fatty acids (OM3s) derived from krill oil. OM3s has clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia (HTG). The Company’s drug candidate is CaPre, an OM3 phospholipid, which is being developed for the treatment of severe hypertriglyceridemia, a condition characterized by abnormally high levels of triglycerides in the bloodstream (over 500 mg/dL) (severe hypertriglyceridemia or severe HTG).

Finance:
Market Cap:191.7M; Shares Outstanding:88M; Short Interest: 2.76%; Q4 2019(12/31/19): Cash 26.23M. Loss 2.82M

EPS and Sales:
https://finance.yahoo.com/quote/ACST/financials?p=ACST

Date EPS % last year % last quarter
2019.3.31 -0.18 -21.05% 80.85%
2019.6.30 -0.67 -79.59% -272.22%
2019.9.30 -0.57 16.67% 14.93%
2019.12.31 -0.72 22.76% -26.32%

 

Sale:0

Insider Transactions:
http://insidercow.com/history/company.jsp?company=ACST&B1=Search%21

Institution Ownership:
https://www.marketbeat.com/stocks/NYSE/ACST/institutional-ownership/

2020.01.13:
Total institutions: 28,no change
Shares hold: 3523k shares. no change
shares% hold: 4.15%,no change

Analyst Ratings:
https://www.tipranks.com/stocks/ACST/price-targe

Leave a Reply